Online citations, reference lists, and bibliographies.
← Back to Search

DYSBOT: A Single‐blind, Randomized Parallel Study To Determine Whether Any Differences Can Be Detected In The Efficacy And Tolerability Of Two Formulations Of Botulinum Toxin Type A—Dysport And Botox—assuming A Ratio Of 4:1

C. Sampaio, J. Ferreira, F. Simões, M. Rosas, M. Magalhães, A. P. Correia, A. Bastos-Lima, R. Martins, A. Castro-Caldas
Published 1997 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background: Elston and Russell discovered a difference in the biological potency of the English formulation of botulinum toxin type A or BTX‐A (Dysport) and the American formulation (Botox). Potency of both is expressed in LD50 mouse units, but because of assay differences, these units are not equivalent. Since the first warning by Quinn and Hallet on the clinical importance of this issue, it has been impossible to reach a consensus on the conversion factor for the potency of these formulations.
This paper references



This paper is referenced by
10.1586/17469872.2.4.417
Botulinum toxin for facial wrinkles: history and future
D. Hexsel (2007)
10.2174/138161209789271843
Current clinical applications of botulinum toxin.
D. Truong (2009)
10.11606/T.5.2015.TDE-17062015-164125
Comparação da eficácia entre a toxina onabotulínica A com a abobotulínica A, na equivalência de 1:3, para o tratamento da assimetria na paralisia facial de longa duração
Adelina F N Remigio (2015)
10.1007/s00702-010-0546-9
Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm
B. Wabbels (2010)
10.2147/NDT.S1612
Neurologic uses of botulinum neurotoxin type A
J. Ney (2007)
10.1016/J.CLINTHERA.2007.07.020
Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
M. A. Chapman (2007)
10.2165/00126839-200809010-00002
Botulinum Toxin for Pain
R. Casale (2008)
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
A. Blitzer (2008)
10.1097/WNF.0000000000000101
A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1 1.7 in the Treatment of Cervical Dystonia A Double-Blind, Randomized, Crossover Trial
A. Rystedt (2015)
10.1046/j.1468-1331.2001.00035.x
Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
K. Aoki (2001)
10.1111/j.1468-1331.2006.01438.x
Pharmacology of botulinum toxin: differences between type A preparations
R. Rosales (2006)
10.1016/S0966-6362(99)00054-5
Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.
H. Graham (2000)
10.1002/mds.20468
Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study
A. Marchetti (2005)
10.1016/S0028-3843(14)60406-0
Czy wszystkie preparaty toksyny botulinowej typu A są takie same? Porównanie trzech preparatów toksyny botulinowej typu A w zarejestrowanych wskazaniach w neurologii
J. Slawek (2010)
10.1007/s11910-010-0129-z
An Update on the Neurologic Applications of Botulinum Toxins
V. Evidente (2010)
10.1007/s12640-009-9023-3
Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs
A. R. Bentivoglio (2009)
10.1016/j.tripleo.2009.10.046
Neurogenic temporomandibular joint dislocation treated with botulinum toxin: report of 4 cases.
Olga Vázquez Bouso (2010)
10.1185/030079905X36396
Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm
K. Bihari (2005)
10.1046/j.1468-1331.2000.00015.x
Alcohol with xylocaine for treatment of eyelid dystonia
A. Mubaidin (2000)
10.3341/JKOS.2009.50.3.331
Clinical Comparability of Dysport and Botox in Essential Blepharospasm
Jae-Ho Shin (2009)
10.1016/B978-012125831-3/50273-2
Chapter 78 – Dyskinesias
H. Topka (2003)
10.2340/00015555-0490
Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis.
A. Rystedt (2008)
10.3109/9781841848525-29
Botulinum toxins in the treatment of dystonia
Mark Stacy (2012)
10.5336/MEDSCI.2012-32060
Efficacy and Safety of Botulinum Toxin Type A (Botox®)' in Blepharospasm and Hemifacial Spasm
Murat Çabalar (2013)
[Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
S. Schellini (2006)
10.1055/a-0834-4188
[Therapy of Hemifacial Spasm with Botulinum Toxin].
W. Jost (2019)
10.2147/BTT.S65603
Botulinum toxin type A products are not interchangeable: a review of the evidence
M. Brin (2014)
10.1017/CBO9780511544866.010
Upper Motor Neurone Syndrome and Spasticity: Spasticity and botulinum toxin
M. Barnes (2008)
10.1002/mds.20829
Comments and corrections on the REAL DOSE study
R. Kingswell (2006)
10.1007/s11940-018-0488-3
Botulinum Toxin Treatment of Movement Disorders
Yasaman Safarpour (2018)
10.1002/14651858.CD000319.PUB4
Medicinal and injection therapies for mechanical neck disorders.
P. Peloso (2005)
10.1007/978-3-319-56038-0_13
Clinical Uses of Botulinum Toxin in the Skin
James Y T Wang (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar